Massachusetts General Hospital
massgeneral.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
2,547
Active
584
Phase 3
96
Total enrollment
2,427,940
Pipeline matrix
Showing 40 of 259 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Infliximab | — | — | — | 5 | |||
| Rituximab | — | — | — | 17 | |||
| Romosozumab | — | — | — | — | 3 | ||
| Denosumab | — | — | — | — | 7 | ||
| Buspirone | — | — | — | 7 | |||
| Prednisone | — | — | — | 6 | |||
| Quetiapine | — | — | — | — | — | 6 | |
| Alendronate | — | — | 6 | ||||
| Propranolol | — | — | — | — | 5 | ||
| Teriparatide | — | — | — | — | 5 | ||
| Pramipexole | — | — | — | — | 3 | ||
| allopurinol | — | — | — | — | 2 | ||
| Theophylline | — | — | — | — | 2 | ||
| Purified Cortophin Gel, 40 U | — | — | — | — | — | 1 | |
| Purified Cortophin Gel 80 U | — | — | — | — | — | 1 | |
| Cariprazine | — | — | — | — | — | 1 | |
| Aripiprazole/Escitalopram combination | — | — | — | — | — | 1 | |
| Lurasidone | — | — | — | — | — | 1 | |
| Aspirin 325mg | — | — | — | — | — | 1 | |
| Enoxaparin 40Mg/0.4mL Prefilled Syringe | — | — | — | — | — | 1 | |
| Conversion to extended-release tacrolimus | — | — | — | — | — | 1 | |
| Maintenance of immediate-release tacrolimus | — | — | — | — | — | 1 | |
| Airsupra | — | — | — | — | — | 1 | |
| APRETUDE | — | — | — | — | — | 1 | |
| Empagliflozin 10 mg | — | — | — | — | — | 1 | |
| Mealatonin | — | — | — | — | — | 1 | |
| Naproxen 250 MG | — | — | — | — | — | 1 | |
| Colchicine 0.6 mg | — | — | — | — | — | 1 | |
| Colchicine 1.2 mg | — | — | — | — | — | 1 | |
| Naproxen 500 Mg | — | — | — | — | — | 1 | |
| Prednisone 40 mg | — | — | — | — | — | 1 | |
| raloxifene | — | — | — | — | — | 1 | |
| GARDASIL®9 | — | — | — | — | — | 1 | |
| Menveo®/Menactra® | — | — | — | — | — | 1 | |
| Lumateperone 42 mg | — | — | — | — | — | 1 | |
| IV TXA | — | — | — | — | — | 1 | |
| Topical TXA | — | — | — | — | — | 1 | |
| Topical saline | — | — | — | — | — | 1 | |
| Sculptra | — | — | — | — | — | 1 | |
| Esketamine | — | — | — | — | — | 1 |
219 more active programs hidden
Next readouts
- 2015-05
- 2016-05
- 2019-04-11
- 2021-09-18
- 2021-12-31
- 2022-02-16
- 2022-03-30
- 2022-07-30
- 2022-10
- 2022-12-02
Top conditions
- Depression102
- Major Depressive Disorder64
- Breast Cancer51
- Bipolar Disorder51
- Obesity47
- Healthy44
- Lung Cancer36
- Schizophrenia34
Frequently asked questions about Massachusetts General Hospital
- How many clinical trials does Massachusetts General Hospital have on ClinicalTrials.gov?
- Massachusetts General Hospital is listed as the lead sponsor on 2,547 clinical trials in ClinicalTrials.gov, 584 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Massachusetts General Hospital's trials are in Phase 3?
- 96 of Massachusetts General Hospital's trials are in Phase 3, spread across 259 active drug programs.
- What therapeutic areas does Massachusetts General Hospital focus on?
- Massachusetts General Hospital's most-studied conditions on ClinicalTrials.gov are Depression, Major Depressive Disorder, Breast Cancer, Bipolar Disorder, Obesity.
- When are Massachusetts General Hospital's next clinical trial readouts?
- Massachusetts General Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations”, expected around 2015-05.